Volume 8, Issue 1, January 2025
Research Articles
Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-Phage-to-Yeast (H2PtY) platform
Statement of Significance: We discovered a common light chain (CLC) bispecific antibody targeting PD-1 and PD-L1 with favorable biophysical properties and potent efficacy. Notably, we have developed a unique and flexible Hybridoma-to-Phage-to-Yeast platform for the generation of CLC bispecific antibodies targeting a given pair of targets.
Humanized anti-CD11d monoclonal antibodies suitable for basic research and therapeutic applications
Statement of Significance: We describe the first humanized monoclonal antibodies to the β2 integrin CD11d alpha chain. These antibodies bind to CD11d on primary human leukocytes and the anti-CD11d-2 clone did not induce outside-in signaling. The screened humanized anti-CD11d clones recapitulate the ability of the mouse parental anti-CD11d to improve neurological outcomes in a rat acute neurotrauma model.
A bioluminescent reporter bioassay for in-process assessment of chimeric antigen receptor lentiviral vector potency
Statement of Significance: We have developed a simple and sensitive bioluminescent reporter bioassay for measuring chimeric antigen receptor–encoding lentiviral vector potency. This assay can be used for in-process quality control during the manufacturing of vectors for cell therapy.
Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule
Statement of Significance: Thirty-six bivalent biparatopic antibodies targeting pairs of nine distinct topographical epitopes distributed over CD30 were developed. These BpAbs exhibited a range of signaling activities from agonism to antagonism, with many displaying reduced signal activation. Notably, 1:1-binding antagonists were developed with no signal induction. The mechanism was elucidated by epitope information.
Review Articles
Practical advice in the development of a lyophilized protein drug product
Statement of Significance: This review offers practical advice on the critical aspects of lyophilized protein drug product development, including considerations across early and late stages of development, formulation strategies for enhancing protein stability and the efficiency of the lyophilization process, selection of primary containers and closures, and considerations in lyophilization cycle development.
Current use and development of monoclonal antibodies for the treatment of systemic lupus erythematosus: a review
Statement of Significance
Among FDA-approved mAbs, anifrolumab is more effective than belimumab, but the latter is not associated with the development of opportunistic infections.
There are several potential antibody developments for the treatment of SLE, whose entry into the clinic is possible within 5–10 years: obinutuzumab to CD20, AMG557 to ICOS, dopyrolizumab pegol to CD40L, and tolizumab to IL6R.
Near-infrared photoimmunotherapy: mechanisms, applications, and future perspectives in cancer research
Statement of Significance: Photoimmunotherapy (PIT) is a tumor-targeted therapy with minimal off-target effects. Recent advances in technology have expanded PIT’s clinical applications, including its approval in Japan for head and neck cancer treatment. This review discusses the application of PIT in cancer therapeutics and its potential in advancing cancer treatments.
